EPO issues new patent to OncoGenex
The new patent entitled, ‘Oligonucleotides for Treatment of Prostate and other Cancers,’ includes coverage for antisense and siRNA compositions that reduce the amount of active Heat Shock Protein
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.